Your session is about to expire
← Back to Search
HDR Brachytherapy for Prostate Cancer (SalvageHDR Trial)
SalvageHDR Trial Summary
This trial is testing the safety and effectiveness of High Dose Rate (HDR) salvage brachytherapy for men with localized prostate cancer.
SalvageHDR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSalvageHDR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.SalvageHDR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not experienced severe side effects from previous radiation therapy.I am unable to understand and agree to the study's procedures and risks.My cancer has returned and is suitable for a specific radiation treatment as determined by ultrasound.I am fit for surgery under anesthesia, including spinal or general.I have not had surgery to remove part of my prostate.I am older than 45 and expected to live more than 10 years.It has been over 3 years since my last external beam radiation therapy.My diagnosis of DIL was confirmed by a biopsy reviewed by a specific pathologist.My bladder empties well and my urine flow is strong.My doctor may start me on hormone therapy for cancer.My prostate cancer has returned in the same place as before.I have never had inflammatory bowel disease or rectal surgery.I've had radiation therapy with specific dose limits.I am fully active or can carry out light work.
- Group 1: HDR partial prostate brachytherapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who qualifies to participate in this trial?
"The investigators of this trial are seeking 15 qualified individuals who have prostate cancer recurrence, aged between 45 and 80. Crucially, participants' PSA doubling time must exceed 6 months with EBRT dose not exceeding 78Gray/39 fractions or 81 Gray/45 fractions or 70 Gray/28 fractions within 3 years; the applicants should also be above 45 in age and possess a life expectancy higher than 10 years as verified by CT scan of abdomen/pelvis & bone scan."
Does the protocol for this medical trial accommodate those over sixty-nine?
"The enrollment requirements of this trial specify that participants must be in between the ages of 45 and 80. On the other hand, 72 trials are open to those younger than 18 while 1,247 studies were created for individuals 65 or older."
Share this study with friends
Copy Link
Messenger